Cd40 - CD40 molecule Gene

Also Known as Tnfrsf5

Species: Rattus norvegicus

Gene Type: protein coding
Gene ID: 171369

Summary

Enables antigen binding activity and protein domain specific binding activity. Involved in several processes, including cellular response to cytokine stimulus; response to cobalamin; and response to interferon-gamma. Located in several cellular components, including cell surface; neuronal cell body; and varicosity. Used to study several diseases, including Ehrlich tumor carcinoma; artery disease (multiple); colitis; membranous glomerulonephritis; and obesity. Biomarker of asthma; atherosclerosis; and perinatal necrotizing enterocolitis. Human ortholog(s) of this gene implicated in several diseases, including Kawasaki disease; autoimmune disease (multiple); end stage renal disease; hyperimmunoglobulin syndrome (multiple); and non-Hodgkin lymphoma (multiple). Orthologous to human CD40 (CD40 molecule). [provided by Alliance of Genome Resources, Apr 2022]

Cd40 Products (1)

mRNA Protein Name
NM_134360.1 NP_599187.1 tumor necrosis factor receptor superfamily member 5 precursor

Gene Ontology

  • Molecular Function
  • Biological Process
  • Cellular Component
Molecular Function GO Annotation Evidence References Source
enables antigen binding IDA
IDA: Inferred from direct assay
22355605 RGD
enables protein domain specific binding IPI
IPI: Inferred from physical interaction
25260678 RGD
Biological Process GO Annotation Evidence References Source
involved in B cell activation IMP
IMP: Inferred from mutant phenotype
27692815 RGD
involved in cellular response to erythropoietin IEP
IEP: Inferred from expression pattern
21649646 RGD
involved in cellular response to interleukin-1 IEP
IEP: Inferred from expression pattern
10403401 RGD
involved in cellular response to lipopolysaccharide IEP
IEP: Inferred from expression pattern
19271152 RGD
involved in cellular response to tumor necrosis factor IEP
IEP: Inferred from expression pattern
10403401 RGD
involved in response to bacterium IEP
IEP: Inferred from expression pattern
22355605 RGD
involved in response to cobalamin IEP
IEP: Inferred from expression pattern
16716410 RGD
involved in response to nutrient levels IEP
IEP: Inferred from expression pattern
21840190 RGD
involved in response to peptide IEP
IEP: Inferred from expression pattern
19457161 RGD
involved in response to type II interferon IEP
IEP: Inferred from expression pattern
10403401 RGD
Cellular Component GO Annotation Evidence References Source
located in cell surface IDA
IDA: Inferred from direct assay
15069176 RGD
located in extracellular space IDA
IDA: Inferred from direct assay
16716410 RGD
located in neuronal cell body IDA
IDA: Inferred from direct assay
25972624 RGD
located in varicosity IDA
IDA: Inferred from direct assay
25972624 RGD
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern
Protein Preferred Names Protein Names

tumor necrosis factor receptor superfamily member 5

  • CD40 antigen, TNF receptor superfamily member 5

  • CD40 molecule, TNF receptor superfamily member 5

  • tumor necrosis factor receptor superfamily, member 5

Recombinant Cd40 Proteins

Cat. No. Product Name Accession Purity
HY-P74295 CD40 Protein, Rat (HEK293, His) A6JXD6/NP_599187.1 (L20-R193) ≥ 95%, as determined by reducing SDS-PAGE.
HY-P74296 CD40 Protein, Rat (HEK293, Fc) A6JXD6 (L20-R193) ≥ 95%, as determined by reducing SDS-PAGE.

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Inhibitory Antibodies (1)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-P9950 Omalizumab Inhibitor 99.70% Unkown

Clinical Phase

Bioactive Molecules (3)
Cat. No. Product Name Effect
Purity Phase
HY-B1618 Corticosterone Agonist 99.77% Phase 3
HY-N6664 Gum arabic / Phase 3
HY-131968 BMS-986202 Inhibitor 99.29% Phase 1
Inhibitory Antibodies (21)
Cat. No. Product Name Effect
Purity Phase
HY-P99625 Frexalimab Inhibitor 99.00% Phase 3
HY-P99845 Dazodalibep 99.0% Phase 3
HY-P99742 Mitazalimab Inhibitor 99.23% Phase 3
HY-P99046 Selicrelumab Agonist 99.29% Phase 2
HY-P99315 Ruplizumab Inhibitor 99.84% Phase 2
HY-P99670 Iscalimab Inhibitor 99.64% Phase 2
HY-P99049 Sotigalimab Agonist 98.90% Phase 2
HY-P990726 Abiprubart 99.00% Phase 2
HY-P99257 Bleselumab Inhibitor 98.97% Phase 2
HY-P99701 Letolizumab Inhibitor 98.32% Phase 2
HY-P99167 Lucatumumab Inhibitor ≥99.0% Phase 2
HY-P99015 Dacetuzumab Inhibitor 95.37% Phase 2
HY-P99821 Ravagalimab Inhibitor 99.31% Phase 2
HY-P99572 Tecaginlimab Inhibitor 99.00% Phase 2
HY-P991525 2141-V11 99.04% Phase 2
HY-P991510 CDX-1140 Agonist / Phase 2
HY-P991554 FFP-104 Modulator / Phase 2
HY-P991556 TQB2916 Agonist / Phase 2
HY-P991921 TNX-1500 Inhibitor / Phase 2
HY-P99325 Toralizumab Inhibitor 99.57% Phase 1
HY-P991666 BMS-986090 Inhibitor / Phase 1

Pre-clinical Phase

Bioactive Molecules (36)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-122663A BIO8898 Inhibitor 98.08% Unkown
HY-120323 DRI-C21045 Inhibitor 98.11% Unkown
HY-110247 TRAF-STOP inhibitor 6877002 Inhibitor 99.67% Unkown
HY-148980A Polyinosinic acid sodium 91.5% Unkown
HY-154821A DRI-C21041 DIEA Inhibitor 99.07% Unkown
HY-153345 Glucocorticoid receptor agonist-1 phosphate(2,6-difluoro) Ala-Ala-Br Agonist 99.67% Unkown
HY-49382 Fluocinolone acetonide 3-benzylaniline 99.93% Unkown
HY-154822 DRI-C25441 Inhibitor 99.53% Unkown
HY-118922 IW927 Inhibitor 99.23% Unkown
HY-152121 Glucocorticoid receptor agonist-1 phosphate Ala-Ala-Mal Agonist 95.68% Unkown
HY-122663 (Rac)-BIO8898 Inhibitor 98.03% Unkown
HY-16668 Tyrphostin A1 Inhibitor 98.96% Unkown
HY-125025 SMI 6860766 Inhibitor / Unkown
HY-154821 DRI-C21041 Inhibitor / Unkown
HY-D1236 Fluorescent brightener 71 Inhibitor / Unkown
HY-P10399 KGYY15 Inhibitor 99.19% Unkown
HY-148980 Polyinosinic acid / Unkown
HY-143410 Anti-inflammatory agent 16 Inhibitor / Unkown
HY-148459 ATAC21 / Unkown
HY-171590 SIK2-IN-3 Inhibitor / Unkown
HY-179701 NIK-IN-3 Inhibitor / Unkown
HY-D1124 Mordant brown 1 / Unkown
HY-D3334 PE-CF594 / Unkown
HY-P10937 AQP4 (205-215) / Unkown
HY-P10937A AQP4 (205-215) TFA / Unkown
HY-RS02246 CD40 Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS02247 CD40LG Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-120471 AM-0687 Inhibitor / Unkown
HY-168384 M04 / Unkown
HY-174737 Human CD40LG mRNA / Unkown
HY-174738 Human CD40 mRNA / Unkown
HY-400878 Glucocorticoid receptor agonist-1 phosphate Gly-Glu-Mal Agonist 99.86% Unkown
HY-RS16527 Cd40 Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS17669 Cd40lg Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS22958 Cd40 Rat Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS24130 Cd40lg Rat Pre-designed siRNA Set A Pre-designed Set / Unkown
Inhibitory Antibodies (21)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-P990680 Anti-Mouse CD40 Antibody (FGK4.5/FGK45) Inhibitor 98.35% Unkown
HY-P99842A Dapirolizumab Inhibitor 99.66% Unkown
HY-P990083 Tegoprubart Inhibitor 99.86% Unkown
HY-P990134 Anti-Mouse CD40L/CD154 Antibody (MR-1) Inhibitor 99.62% Unkown
HY-P990860 Anti-CD40 Antibody (G28.5) Inhibitor 95.00% Unkown
HY-P990133 Anti-Monkey/Human CD40L/CD154 Antibody (5C8) Inhibitor 95.00% Unkown
HY-P990111 BMS-986325 (anti-CD40) Inhibitor 99.84% Unkown
HY-P991513 BI-655064 Inhibitor 98.56% Unkown
HY-P99321 Teneliximab Inhibitor ≥99.0% Unkown
HY-P991126 Ciltistotug Ligand 95.376% Unkown
HY-P99663 Inezetamab Inhibitor 99.77% Unkown
HY-P990269 Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) Inhibitor 95.00% Unkown
HY-P991086 MGD010 Inhibitor 99.06% Unkown
HY-P990083A Tegoprubart (powder) Inhibitor / Unkown
HY-P990270 Anti-Mouse CD40L/CD154 (D265A) Antibody (MR-1) / Unkown
HY-P991460 Sym029 Agonist / Unkown
HY-P991555 XmAb5485 Inducer / Unkown
HY-P991557 ABI793 Inhibitor / Unkown
HY-P991918 KHK2840 Agonist / Unkown
HY-P991919 SBT-040 / Unkown
HY-P992408 MEDI-5083 / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Cd40 NCBI NCBI:958